Goldman Sachs Group Inc Revance Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,163,371 shares of RVNC stock, worth $2.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,163,371
Previous 933,618 24.61%
Holding current value
$2.99 Million
Previous $2.4 Million 24.59%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.57 - $2.57 $590,465 - $590,465
229,753 Added 24.61%
1,163,371 $2.99 Million
Q2 2024

Aug 13, 2024
BUY
$2.34 - $4.73 $912,995 - $1.85 Million
390,169 Added 71.79%
933,618 $2.4 Million
Q1 2024

May 15, 2024
SELL
$4.65 - $9.31 $1.12 Million - $2.24 Million
-240,179 Reduced 30.65%
543,449 $2.67 Million
Q4 2023

Feb 13, 2024
SELL
$5.81 - $11.2 $2.1 Million - $4.04 Million
-361,016 Reduced 31.54%
783,628 $6.89 Million
Q3 2023

May 14, 2024
BUY
$11.47 - $25.07 $4.14 Million - $9.05 Million
361,016 Added 46.07%
1,144,644 $13.1 Million
Q3 2023

Nov 14, 2023
SELL
$11.47 - $25.07 $6.84 Million - $14.9 Million
-596,258 Reduced 34.25%
1,144,644 $13.1 Million
Q2 2023

May 14, 2024
BUY
$24.7 - $37.61 $15.9 Million - $24.2 Million
642,612 Added 58.51%
1,740,902 $44.1 Million
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $15.9 Million - $24.2 Million
642,612 Added 58.51%
1,740,902 $44.1 Million
Q1 2023

May 14, 2024
SELL
$18.36 - $35.27 $2.09 Million - $4.01 Million
-113,570 Reduced 9.37%
1,098,290 $35.4 Million
Q1 2023

May 11, 2023
SELL
$18.36 - $35.27 $2.09 Million - $4.01 Million
-113,570 Reduced 9.37%
1,098,290 $35.4 Million
Q4 2022

May 14, 2024
BUY
$18.32 - $30.66 $1.32 Million - $2.21 Million
72,052 Added 6.32%
1,211,860 $22.4 Million
Q4 2022

Feb 13, 2023
BUY
$18.32 - $30.66 $1.32 Million - $2.21 Million
72,052 Added 6.32%
1,211,860 $22.4 Million
Q3 2022

May 14, 2024
BUY
$14.33 - $28.47 $4.45 Million - $8.85 Million
310,883 Added 37.5%
1,139,808 $30.8 Million
Q3 2022

Nov 10, 2022
BUY
$14.33 - $28.47 $4.45 Million - $8.85 Million
310,883 Added 37.5%
1,139,808 $30.8 Million
Q2 2022

May 14, 2024
BUY
$11.52 - $20.4 $521,821 - $924,058
45,297 Added 5.78%
828,925 $11.5 Million
Q2 2022

Aug 15, 2022
BUY
$11.52 - $20.4 $1.99 Million - $3.52 Million
172,369 Added 26.25%
828,925 $11.5 Million
Q1 2022

May 16, 2022
SELL
$12.36 - $20.31 $1.85 Million - $3.04 Million
-149,476 Reduced 18.54%
656,556 $12.8 Million
Q4 2021

Feb 14, 2022
BUY
$12.46 - $27.87 $2.63 Million - $5.89 Million
211,332 Added 35.54%
806,032 $13.2 Million
Q3 2021

Nov 10, 2021
BUY
$25.78 - $33.21 $15.3 Million - $19.7 Million
594,700 New
594,700 $16.6 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email